Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 10, 2006 - Issue 1
Submit an article Journal homepage
832
Views
190
CrossRef citations to date
0
Altmetric
Review

From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer

Bharat B Aggarwal Ransom Horne, Jr., Professor of Cancer Research, Professor of Cancer Medicine (Biochemistry), and Chief, Cytokine Research Laboratory, The University of Texas, MD Anderson Cancer Center, Cytokine Research Laboratory, Department of Experimental Therapeutics, Box 143, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. [email protected]
,
Haruyo Ichikawa Postdoctoral Fellow, The University of Texas, MD Anderson Cancer Center, Cytokine Research Laboratory, Department of Experimental Therapeutics, Box 143, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
,
Prachi Garodia Doctor, The University of Texas, MD Anderson Cancer Center, Cytokine Research Laboratory, Department of Experimental Therapeutics, Box 143, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
,
Priya Weerasinghe Instructor, The University of Texas, MD Anderson Cancer Center, Cytokine Research Laboratory, Department of Experimental Therapeutics, Box 143, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
,
Gautam Sethi Postdoctoral Fellow, The University of Texas, MD Anderson Cancer Center, Cytokine Research Laboratory, Department of Experimental Therapeutics, Box 143, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
,
Indra D Bhatt Postdoctoral Fellow, The University of Texas, MD Anderson Cancer Center, Cytokine Research Laboratory, Department of Experimental Therapeutics, Box 143, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
,
Manoj K Pandey Postdoctoral Fellow, The University of Texas, MD Anderson Cancer Center, Cytokine Research Laboratory, Department of Experimental Therapeutics, Box 143, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
,
Shishir Shishodia Assistant Professor, Texas Southern University, Department of Biology, 3100 Cleburne Street, Houston, Texas 77004, USA
&
Muraleedharan G Nair Professor, Michigan State University, 173 National Food Safety and Toxicology Center, East Lansing, MI 48824, USA
 show all
Pages 87-118 | Published online: 27 Jan 2006

Bibliography

  • NEWMAN DJ, CRAGG GM, SNADER KM: Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. (2003) 66:1022-1037.
  • CRAIG WJ: Phytochemicals: guardians of our health. J. Am. Diet. Assoc. (1997) 97:S199-S204.
  • CRAIG WJ: Health-promoting properties of common herbs. Am. J. Clin. Nutr. (1999) 70:491S-499S.
  • COUSSENS LM, WERB Z: Inflammation and cancer. Nature (2002) 420:860-867.
  • BALKWILL F, MANTOVANI A: Inflammation and cancer: back to Virchow? Lancet (2001) 357:539-545.
  • HAHN WC, WEINBERG RA: Rules for making human tumor cells. N. Engl. J. Med. (2002) 347:1593-1603.
  • AGGARWAL BB: Nuclear factor-kappaB: the enemy within. Cancer Cell (2004) 6:203-208.
  • EFERL R, WAGNER EF: AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer (2003) 3:859-868.
  • GARG A, AGGARWAL BB: Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia (2002) 16:1053-1068.
  • KORUTLA L, CHEUNG YJ, MENDELSOHN J, KUMAR R: Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis (1995) 16:1741-1745.
  • HONG RL, SPOHN WH, HUNG MC: Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin. Cancer Res. (1999) 5:1884-1891.
  • YU H, JOVE R: The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer (2004) 4:97-105.
  • HONG J, LAMBERT JD, LEE SH et al.: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem. Biophys. Res. Commun. (2003) 310:222-227.
  • LO MUZIO L, STAIBANO S, PANNONE G et al.: The human multidrug resistance gene (MDR-1): immunocytochemical detection of its expression in oral SCC. Anti-Cancer Res. (2000) 20:2891-2897.
  • JAIN V, DAS SN, LUTHRA K et al.: Differential expression of multidrug resistance gene product, P-glycoprotein, in normal, dysplastic and malignant oral mucosa in India. Int. J. Cancer (1997) 74:128-133.
  • KIM WJ, KAKEHI Y, WU WJ et al.: Expression of multidrug resistance-related genes (mdrl, MRP, GST-pi and DNA topoisomerase II) in urothelial cancers. Br. J. Urol. (1996) 78:361-368.
  • SUBBARAMAIAH K, DANNENBERG AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. (2003) 24:96-102.
  • FOLKMAN J: Fundamental concepts of the angiogenic process. Curr. Mol. Med. (2003) 3:643-651.
  • HENDRIX MJ, SEFTOR EA, HESS AR, SEFTOR RE: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer (2003) 3:411-421.
  • SHERR CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. (2000) 60:3689-3695.
  • CHARAKA: Charaka Samhita. Chaukhamba Orientalia. Varanasi, India (700 BC).
  • SUSRUTA: Susruta Samhita. Chaukhamba Surbharati Publications. Varanasi, India (700 BC).
  • MISRA B: Bhawa Prakash Nighantu. Chaukhamba Publications. Varanasi, India (1600 AD).
  • KAPOOR LD: Handbook of ayurvedic medicinal plants. CRC Press. Florida (1990).
  • BALACHANDRAN P, GOVINDARAJAN R: Cancer-an ayurvedic perspective. Pharmacol. Res. (2005) 51:19-30.
  • SINGH RH: An assessment of the ayurvedic concept of cancer and a new paradigm of anticancer treatment in Ayurveda. J. Altern. Complement. Med. (2002) 8:609-614.
  • SMIT HF, WOERDENBAG HJ, SINGH RH et al.: Ayurvedic herbal drugs with possible cytostatic activity. J. Ethnopharmacol. (1995) 47:75-84.
  • URIZAR NL, MOORE DD: GUGULIPID: A natural cholesterol-lowering agent. Ann. Rev. Nutr. (2003) 23:303-313.
  • SINAL CJ, GONZALEZ FJ: Guggulsterone: an old approach to a new problem. Trends Endocrinol. Metab. (2002) 13:275-276.
  • GUJRAL ML, SAREEN K, TANGRI KK et al.: Antiarthritic and anti-inflammatory activity of gum guggul (Balsamodendron mukul Hook). Indian J. Physiol. Pharmacol. (1960) 4:267-273.
  • SHARMA JN: Comparison of the anti-inflammatory activity of Commiphora mukul (an indigenous drug) with those of phenylbutazone and ibuprofen in experimental arthritis induced by mycobacterial adjuvant. Arzneimittelforschung (1977) 27:1455-1457.
  • SINGH BB, MISHRA LC, VINJAMURY SP et al.: The effectiveness of Commiphora mukul for osteoarthritis of the knee: an outcomes study. Altern. Ther. Health Med. (2003) 9:74-79.
  • URIZAR NL, LIVERMAN AB, DODDS DT et al.: A natural product that lowers cholesterol as an antagonist ligand for FXR. Science (2002) 296:1703-1706.
  • WU J, XIA C, MEIER J et al.: The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol. Endocrinol. (2002) 16:1590-1597.
  • CUI J, HUANG L, ZHAO A et al.: Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. (2003) 278:10214-10220.
  • MESELHY MR: Inhibition of LPS-induced NO production by the oleogum resin of Commiphora wightii and its constituents. Phytochemistry (2003) 62:213-218.
  • YAMAMOTO Y, GAYNOR RB: Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J. Clin. Invest. (2001) 107:135-142.
  • SHISHODIA S, AGGARWAL BB: Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J. Biol. Chem. (2004) 279:47148-47158.
  • BHARTI AC, DONATO N, AGGARWAL BB: Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. (2003) 171:3863-3871.
  • ANTO RJ, MUKHOPADHYAY A, DENNING K, AGGARWAL BB: Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis (2002) 23:143-150.
  • MUKHOPADHYAY A, BUESO-RAMOS C, CHATTERJEE D et al.: Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene (2001) 20:7597-7609.
  • MUKHOPADHYAY A, BANERJEE S, STAFFORD LJ et al.: Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene (2002) 21:8852-8861.
  • AGGARWAL BB, KUMAR A, BHARTI AC: Anticancer potential of curcumin: preclinical and clinical studies. Anti-Cancer Res. (2003) 23:363-398.
  • SHISHODIA S, POTDAR P, GAIROLA CG, AGGARWAL BB: Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis (2003) 24:1269-1279.
  • BHARTI AC, TAKADA Y, AGGARWAL B: Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J. Immunol. (2004) 172:5940-5947.
  • BHARTI AC, SHISHODIA S, REUBEN JM et al.: Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood (2004) 103:3175-3184.
  • BHARTI AC, DONATO N, SINGH S, AGGARWAL BB: Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood (2003) 101:1053-1062.
  • AGGARWAL S, TAKADA Y, SINGH S et al.: Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int. J. Cancer (2004) 111:679-692.
  • AGGARWAL BB, TAKADA Y, OOMMEN OV: From chemoprevention to chemotherapy: common targets and common goals. Expert Opin. Investig. Drugs (2004) 13:1327-1338.
  • LI L, AGGARWAL BB, SHISHODIA S et al.: Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer (2004) 101:2351-2362.
  • DORAI T, AGGARWAL BB: Role of chemopreventive agents in cancer therapy. Cancer Lett. (2004) 215:129-140.
  • TAKADA Y, BHARDWAJ A, POTDAR P, AGGARWAL BB: Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene (2004) 23:9247-9258.
  • AGGARWAL BB, SHISHODIA S: Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. NY Acad. Sci. (2004) 1030:434-441.
  • BHARTI AC, TAKADA Y, AGGARWAL BB: PARP cleavage and caspase activity to assess chemosensitivity. Methods Mol. Med. (2005) 111:69-78.
  • SIWAK DR, SHISHODIA S, AGGARWAL BB, KURZROCK R: Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer (2005) 104:879-890.
  • SHISHODIA S, AMIN HM, LAI R, AGGARWAL BB: Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. (2005) 70:700-713.
  • YAN C, JAMALUDDIN MS, AGGARWAL B et al.: Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol. Cancer Ther. (2005) 4:233-241.
  • SHISHODIA S, GETHI G, AGGARWAL BB: Curcumin: Getting back to the roots. Ann. N. Y. Acad. Sci. (2005) (In Press).
  • AGGARWAL BB, KUMAR A, BHARTI AC: Therapeutic potential of curcumin derived from turmeric (Curcuma longa). Marcel Dekker. New York (2004).
  • AGGARWAL BB, KUMER S, AGGARWAL S, SHISHODIA S: Curcumin derived from turmeric (Curcuma longa): A spice for all seasons. In: Phytochmeicals in Cancer Chemoprevention, Bagchi D, Preuss HG (Eds.), CRC press (2005).
  • PAUL B, MASIH I, DEOPUJARI J, CHARPENTIER C: Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. J. Ethnopharmacol. (1999) 68:71-76.
  • MANNA SK, MUKHOPADHYAY A, AGGARWAL BB: Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. (2000) 164:6509-6519.
  • BANERJEE S, BUESO-RAMOS C, AGGARWAL BB: Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. (2002) 62:4945-4954.
  • ESTROV Z, SHISHODIA S, FADERL S et al.: Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood (2003) 102:987-995.
  • AGGARWAL BB, BHARDWAJ A, AGGARWAL RS et al.: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anti-Cancer Res. (2004) 24:2783-2840.
  • CARLSON BA, DUBAY MM, SAUSVILLE EA et al.: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. (1996) 56:2973-2978.
  • LOSIEWICZ MD, CARLSON BA, KAUR G et al.: Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. (1994) 201:589-595.
  • DE AZEVEDO WF Jr, MUELLER-DIECKMANN HJ, SCHULZE-GAHMEN U et al.: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA (1996) 93:2735-2740.
  • WORLAND PJ, KAUR G, STETLER-STEVENSON M et al.: Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem. Pharmacol. (1993) 46:1831-1840.
  • KAUR G, STETLER-STEVENSON M, SEBERS S et al.: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. (1992) 84:1736-1740.
  • BIBLE KC, KAUFMANN SH: Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. (1996) 56:4856-4861.
  • KONIG A, SCHWARTZ GK, MOHAMMAD RM et al.: The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood (1997) 90:4307-4312.
  • ARGUELLO F, ALEXANDER M, STERRY JA et al.: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood (1998) 91:2482-2490.
  • BYRD JC, SHINN C, WASELENKO JK et al.: Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood (1998) 92:3804-3816.
  • GOJO I, ZHANG B, FENTON RG: The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin. Cancer Res. (2002) 8:3527-3538.
  • PATEL V, SENDEROWICZ AM, PINTO D Jr et al.: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Invest. (1998) 102:1674-1681.
  • SHAPIRO GI, SUPKO JG, PATTERSON A et al.: A Phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin. Cancer Res. (2001) 7:1590-1599.
  • SENDEROWICZ AM, SAUSVILLE EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (2000) 92:376-387.
  • KARP JE, ROSS DD, YANG W et al.: Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a Phase I clinical trial. Clin. Cancer Res. (2003) 9:307-315.
  • BIBLE KC, KAUFMANN SH: Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. (1997) 57:3375-3380.
  • NAHTA R, IGLEHART JD, KEMPKES B, SCHMIDT EV: Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res. (2002) 62:2267-2271.
  • WU K, WANG C, D’AMICO M et al.: Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol. Cancer Ther. (2002) 1:695-706.
  • CARTEE L, MAGGIO SC, SMITH R et al.: Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol. Mol. Cancer Ther. (2003) 2:83-93.
  • KIM DM, KOO SY, JEON K et al.: Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res. (2003) 63:621-626.
  • TAKADA Y, AGGARWAL BB: Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J. Biol. Chem. (2004) 279:4750-4759.
  • KITAYAMA T, OKAMOTO T, HILL RK et al.: Chemistry of zerumbone. 1. Simplified isolation, conjugate addition reactions, and a unique ring contracting transannular reaction of its dibromide. J. Org. Chem. (1999) 64:2667-2672.
  • DEV S: Zermbone, a monocytclic sesquiterpene ketone. Chem. & Ind. (1956):1051.
  • MURAKAMI A, TAKAHASHI M, JIWAJINDA S et al.: Identification of zerumbone in Zingiber zerumbet Smith as a potent inhibitor of 12-O-tetradecanoylphorbol-13-acetate-induced Epstein-Barr virus activation. Biosci. Biotechnol. Biochem. (1999) 63:1811-1812.
  • MURAKAMI A, TAKAHASHI D, KOSHIMIZU K, OHIGASHI H: Synergistic suppression of superoxide and nitric oxide generation from inflammatory cells by combined food factors. Mutat. Res. (2003) 523-524:151-161.
  • TANAKA T, SHIMIZU M, KOHNO H et al.: Chemoprevention of azoxymethane-induced rat aberrant crypt foci by dietary zerumbone isolated from Zingiber zerumbet. Life Sci. (2001) 69:1935-1945.
  • MURAKAMI A, TANAKA T, LEE JY et al.: Zerumbone, a sesquiterpene in subtropical ginger, suppresses skin tumor initiation and promotion stages in ICR mice. Int. J. Cancer (2004) 110:481-490.
  • OZAKI Y, KAWAHARA N, HARADA M: Anti-inflammatory effect of Zingiber cassumunar Roxb and its active principles. Chem. Pharm. Bull. (Tokyo) (1991) 39:2353-2356.
  • KIRANA C, MCINTOSH GH, RECORD IR, JONES GP: Antitumor activity of extract of Zingiber aromaticum and its bioactive sesquiterpenoid zerumbone. Nutr. Cancer (2003) 45:218-225.
  • MURAKAMI A, TAKAHASHI D, KINOSHITA T et al.: Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the alpha,beta-unsaturated carbonyl group is a prerequisite. Carcinogenesis (2002) 23:795-802.
  • MURAKAMI A, HAYASHI R, TANAKA T et al.: Suppression of dextran sodium sulfate-induced colitis in mice by zerumbone, a subtropical ginger sesquiterpene, and nimesulide: separately and in combination. Biochem. Pharmacol. (2003) 66:1253-1261.
  • MURAKAMI A, MATSUMOTO K, KOSHIMIZU K, OHIGASHI H: Effects of selected food factors with chemopreventive properties on combined lipopolysaccharide- and interferon-gamma-induced IkappaB degradation in RAW264.7 macrophages. Cancer Lett. (2003) 195:17-25.
  • TAKADA Y, MURAKAMI A, AGGARWAL BB: Zerumbone abolishes NF-kappaB and IkappaBalpha kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. Oncogene (2005) 24:6957-6969.
  • KIRTIKAR KR, BASU BD: Indian Medicinal Plants (1935).
  • NO AUTHORS LISTED: Hager’s handbuch der Pharmazeut, Praxis, Springer-Verlag. Berlin (1972).
  • NO AUTHORS LISTED: The Wealth of India; Raw Materials, CSIR publications, Delhi (1948).
  • REDDY GK, CHANDRAKASAN G, DHAR SC: Studies on the metabolism of glycosaminoglycans under the influence of new herbal anti-inflammatory agents. Biochem. Pharmacol. (1989) 38:3527-3534.
  • SAFAYHI H, MACK T, SABIERAJ J et al.: Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J. Pharmacol. Exp. Ther. (1992) 261:1143-1146.
  • SAFAYHI H, SAILER ER, AMMON HP: Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol. Pharmacol. (1995) 47:1212-1216.
  • AMMON HP, SAFAYHI H, MACK T, SABIERAJ J: Mechanism of antiinflammatory actions of curcumine and boswellic acids. J. Ethnopharmacol. (1993) 38:113-119.
  • KAPIL A, MOZA N: Anticomplementary activity of boswellic acids-an inhibitor of C3-convertase of the classical complement pathway. Int. J. Immunopharmacol. (1992) 14:1139-1143.
  • SAFAYHI H, RALL B, SAILER ER, AMMON HP: Inhibition by boswellic acids of human leukocyte elastase. J. Pharmacol. Exp. Ther. (1997) 281:460-463.
  • GERHARDT H, SEIFERT F, BUVARI P et al.: [Therapy of active Crohn disease with Boswellia serrata extract H 15]. Z. Gastroenterol. (2001) 39:11-17.
  • GUPTA I, PARIHAR A, MALHOTRA P et al.Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur. J. Med. Res. (1997) 2:37-43.
  • KRIEGLSTEIN CF, ANTHONI C, RIJCKEN EJ et al.: Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int. J. Colorectal Dis. (2001) 16:88-95.
  • REDDY GK, DHAR SC: Effect of a new non-steroidal anti-inflammatory agent on lysosomal stability in adjuvant induced arthritis. Ital. J. Biochem. (1987) 36:205-217.
  • SHARMA ML, BANI S, SINGH GB: Anti-arthritic activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis. Int. J. Immunopharmacol. (1989) 11:647-652.
  • SAFAYHI H, MACK T, AMMON HP: Protection by boswellic acids against galactosamine/endotoxin-induced hepatitis in mice. Biochem. Pharmacol. (1991) 41:1536-1537.
  • KIMMATKAR N, THAWANI V, HINGORANI L, KHIYANI R: Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee-a randomized double blind placebo controlled trial. Phytomedicine (2003) 10:3-7.
  • WINKING M, SARIKAYA S, RAHMANIAN A et al.: Boswellic acids inhibit glioma growth: a new treatment option? J. Neurooncol. (2000) 46:97-103.
  • GLASER T, WINTER S, GROSCURTH P et al.: Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br. J. Cancer (1999) 80:756-765.
  • JING Y, NAKAJO S, XIA L et al.: Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. Leuk. Res. (1999) 23:43-50.
  • SHAO YC, HO T, CHIN CK et al.: Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. Planta Med. (1998) 64:328-331.
  • LIU JJ, NILSSON A, OREDSSON S et al.: Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis (2002) 23:2087-2093.
  • ZHAO W, ENTSCHLADEN F, LIU H et al.: Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells. Cancer Detect. Prev. (2003) 27:67-75.
  • HUANG MT, BADMAEV V, DING Y et al.: Anti-tumor and anti-carcinogenic activities of triterpenoid, beta-boswellic acid. Biofactors (2000) 13:225-230.
  • STEINMETZ KA, POTTER JD: Vegetables, fruit, and cancer prevention: a review. J. Am. Diet. Assoc. (1996) 96:1027-1039.
  • TAKADA Y, ANDREEFF M, AGGARWAL BB: Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood (2005) 106:641-649.
  • AGGARWAL BB, ICHIKAWA H: Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle (2005) 4:1201-1215.
  • GARG AK, BUCHHLOZ TA, AGGARWAL BB: Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxidant and Redox Signaling (2005) (In Press).
  • DEVI PU, RAO BS, SOLOMON FE: Effect of plumbagin on the radiation induced cytogenetic and cell cycle changes in mouse Ehrlich ascites carcinoma in vivo. Indian J. Exp. Biol. (1998) 36:891-895.
  • SHARADA AC, SOLOMON FE, DEVI PU et al.: Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. Acta Oncol. (1996) 35:95-100.
  • GANASOUNDARI A, ZARE SM, DEVI PU: Modification of bone marrow radiosensensitivity by medicinal plant extracts. Br. J. Radiol. (1997) 70:599-602.
  • CHENDIL D, RANGA RS, MEIGOONI D et al.: Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene (2004) 23:1599-1607.
  • JAGETIA GC, NAYAK V, VIDYASAGAR MS: Evaluation of the antineoplastic activity of guduchi (Tinospora cordifolia) in cultured HeLa cells. Cancer Lett. (1998) 127:71-82.
  • JAGETIA GC, VENKATESHA VA: Effect of mangiferin on radiation-induced micronucleus formation in cultured human peripheral blood lymphocytes. Environ. Mol. Mutagen. (2005) 46:12-21.
  • JAGETIA GC, BALIGA MS, MALAGI KJ, SETHUKUMAR KAMATH M: The evaluation of the radioprotective effect of Triphala (an ayurvedic rejuvenating drug) in the mice exposed to gamma-radiation. Phytomedicine (2002) 9:99-108.
  • JAGETIA GC, BALIGA MS: Treatment with Alstonia scholaris enhances radiosensitivity in vitro and in vivo. Cancer Biother. Radiopharm. (2003) 18:917-929.
  • YOUNT G, QIAN Y, MOORE D et al.: Berberine sensitizes human glioma cells, but not normal glial cells, to ionizing radiation in vitro. J. Exp. Ther. Oncol. (2004) 4:137-143.
  • SAMAILA DB, TOY J, WANG RC, ELEGBEDE JA: Monoterpenes enhanced the sensitivity of head and neck cancer cells to radiation treatment in vitro. Anti-Cancer Res. (2004) 24:3089-3095.
  • HORSMAN MR, SIEMANN DW, CHAPLIN DJ, OVERGAARD J: Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother. Oncol. (1997) 45:167-174.
  • HARBOTTLE A, DALY AK, ATHERTON K, CAMPBELL FC: Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int. J. Cancer (2001) 92:777-783.
  • IERSEL ML, PLOEMEN JP, STRUIK I et al.: Inhibition of glutathione S-transferase activity in human melanoma cells by alpha,beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem. Biol. Interact. (1996) 102:117-132.
  • DUVOIX A, MORCEAU F, DELHALLE S et al.: Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. Biochem. Pharmacol. (2003) 66:1475-1483.
  • OGISO Y, TOMIDA A, LEI S et al.: Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. (2000) 60:2429-2434.
  • JANA NR, DIKSHIT P, GOSWAMI A, NUKINA N: Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J. Biol. Chem. (2004) 279:11680-11685.
  • FULDA S, DEBATIN KM: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. (2004) 64:337-346.
  • DEVI PU: Withania somnifera Dunal (Ashwagandha): potential plant source of a promising drug for cancer chemotherapy and radiosensitization. Indian J. Exp. Biol. (1996) 34:927-932.
  • SINGH I, SHARMA A, NUNIA V, GOYAL PK: Radioprotection of Swiss albino mice by Emblica officinalis. Phytother. Res. (2005) 19:444-446.
  • PRASAD NS, RAGHAVENDRA R, LOKESH BR, NAIDU KA: Spice phenolics inhibit human PMNL 5-lipoxygenase. Prostaglandins Leukot. Essent. Fatty Acids (2004) 70:521-528.
  • ZHOU S, LIM LY, CHOWBAY B: Herbal modulation of P-glycoprotein. Drug Metab. Rev. (2004) 36:57-104.
  • SHOBA G, JOY D, JOSEPH T et al.: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. (1998) 64:353-356.
  • LAMBERT JD, HONG J, KIM DH et al.: Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice. J. Nutr. (2004) 134:1948-1952.
  • PALUMBO G, BACCHI S, PALUMBO P et al.: [Grapefruit juice: potential drug interaction]. Clin. Ter. (2005) 156:97-103.
  • LE GOFF-KLEIN N, KLEIN L, HERIN M et al.: Inhibition of in-vitro simvastatin metabolism in rat liver microsomes by bergamottin, a component of grapefruit juice. J. Pharm. Pharmacol. (2004) 56:1007-1014.
  • LILJA JJ, NEUVONEN M, NEUVONEN PJ: Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br. J. Clin. Pharmacol. (2004) 58:56-60.
  • LILJA JJ, KIVISTO KT, NEUVONEN PJ: Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin. Pharmacol. Ther. (2000) 68:384-390.
  • ANKE J, RAMZAN I: Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J. Ethnopharmacol. (2004) 93:153-160.
  • SINGH YN: Potential for interaction of kava and St. John’s wort with drugs. J. Ethnopharmacol. (2005) 100:108-113.
  • AROLD G, DONATH F, MAURER A et al.: No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John’s wort extract. Planta Med. (2005) 71:331-337.
  • SMITH P, BULLOCK JM, BOOKER BM et al.: The influence of St. John’s wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy (2004) 24:1508-1514.
  • MANNEL M: Drug interactions with St John’s wort : mechanisms and clinical implications. Drug Saf. (2004) 27:773-797.
  • KHAN S, BALICK MJ: Therapeutic plants of Ayurveda: a review of selected clinical and other studies for 166 species. J. Altern. Complement. Med. (2001) 7:405-515.
  • SAXENA S, PANT N, JAIN DC, BHAKUNI RS: Antimalarial agents from plant sources. Curr. Sci. (2003) 85:1314-1329.
  • THOMAS SC: Medicinal plants: Culture, utilization and phytopharmacology, Techno Publishing Co., Inc., USA (2000).
  • ROTBLATT M, ZIMENT I: Evidence based herbal medicine, Hanley & Belfus, Inc. (2001).
  • MILLER LG, MURRAY WJ: Herbal medicine: A clinician’s guide, Pharmaceuticals Products Press, NY (1998).
  • NO AUTHORS LISTED: PDR For Herbal medicines, Medical Economics Company, Montvale, New Jersey (1999).
  • TEWARI L: Traditional Himalayan Medicine System and its Materia Medica, HIST, India (2001).

Website

  • http://www.clinicaltrials.gov A service of the US National Institute of Health (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.